Abstract

Assessing the Compatibility of Different Formulations in OrPhyllo™, A Ready-to-Use Base for Personalized Orodispersible Films

Author(s): Marianni Bruna, Polonini Hudson, Koulouridas Savvas

Issue: Mar/Apr 2025 - Volume 29, Number 2

Page(s): 163-175

Download in electronic PDF format for $75
  • Assessing the Compatibility of Different Formulations in OrPhyllo™, A Ready-to-Use Base for Personalized Orodispersible Films Page 1
  • Assessing the Compatibility of Different Formulations in OrPhyllo™, A Ready-to-Use Base for Personalized Orodispersible Films Page 2
  • Assessing the Compatibility of Different Formulations in OrPhyllo™, A Ready-to-Use Base for Personalized Orodispersible Films Page 3
  • Assessing the Compatibility of Different Formulations in OrPhyllo™, A Ready-to-Use Base for Personalized Orodispersible Films Page 4
  • Assessing the Compatibility of Different Formulations in OrPhyllo™, A Ready-to-Use Base for Personalized Orodispersible Films Page 5
  • Assessing the Compatibility of Different Formulations in OrPhyllo™, A Ready-to-Use Base for Personalized Orodispersible Films Page 6
  • Assessing the Compatibility of Different Formulations in OrPhyllo™, A Ready-to-Use Base for Personalized Orodispersible Films Page 7
  • Assessing the Compatibility of Different Formulations in OrPhyllo™, A Ready-to-Use Base for Personalized Orodispersible Films Page 8
  • Assessing the Compatibility of Different Formulations in OrPhyllo™, A Ready-to-Use Base for Personalized Orodispersible Films Page 9
  • Assessing the Compatibility of Different Formulations in OrPhyllo™, A Ready-to-Use Base for Personalized Orodispersible Films Page 10
  • Assessing the Compatibility of Different Formulations in OrPhyllo™, A Ready-to-Use Base for Personalized Orodispersible Films Page 11
  • Assessing the Compatibility of Different Formulations in OrPhyllo™, A Ready-to-Use Base for Personalized Orodispersible Films Page 12
  • Assessing the Compatibility of Different Formulations in OrPhyllo™, A Ready-to-Use Base for Personalized Orodispersible Films Page 13

Abstract

Orodispersible films (ODFs) represent a rapidly evolving dosage form that addresses significant challenges in drug delivery, particularly for patients with difficulty swallowing, such as pediatric, geriatric, and psychiatric populations. ODFs disintegrate rapidly on the tongue, eliminating the need for water and offering benefits such as improved patient compliance, faster onset of action, and enhanced bioavailability. This study evaluates the compatibility and beyond-use dates (BUDs) of 12 ODF formulations compounded in OrPhyllo™, a ready-to-use base specifically designed for ODF production. The active pharmaceutical ingredients (APIs) investigated were baclofen (5 and 10 mg), cetirizine (1.25 and 5 mg), coenzyme Q10 (10 and 50 mg), dextromethorphan (7.5 and 15 mg), ketoprofen (12.5 and 25 mg), loratadine (5 and 10 mg), meloxicam (5 and 20 mg), minoxidil (1 and 10 mg), ondansetron (2 and 8 mg), sildenafil (25 and 50 mg), tadalafil (5 and 20 mg), and tramadol (25 and 50 mg). Comprehensive compatibility studies were conducted to determine the BUD and physicochemical integrity of these formulations by using validated ultra-high-performance liquid chromatography (UHPLC) methods and following guidelines for accelerated and long-term stability testing. No Antimicrobial Effectiveness Testing (AET) was conducted as those are nonaqueous dosage forms. The formulations were stored at room temperature (15-30°C) for up to 180 days, individually packed in matte laminated aluminum sachets. Results revealed the following BUDs for each formulation: baclofen (5 mg - 10 mg): 180 days; cetirizine: 60 days; coenzyme Q10: 180 days; dextromethorphan: 180 days; ketoprofen (12.5 mg): 180 days; ketoprofen (>12 mg - 25 mg): 60 days; loratadine: 180 days; meloxicam: 180 days; minoxidil: 180 days; ondansetron (2 mg): 90 days; ondansetron (>2 mg - 8 mg): 30 days; sildenafil: 180 days; tadalafil: 180 days; tramadol: 150 days. These findings affirm the suitability of OrPhyllo™ as a robust vehicle for compounding ODFs, demonstrating compatibility with APIs across a broad spectrum of clinical applications.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2025
Pg. 163-175
Nov/Dec 2025
Pg. 495-504
Mar/Apr 2018
Pg. 108-121
Nov/Dec 2017
Pg. 454-461
Nov/Dec 2018
Pg. 512-515
Jul/Aug 2023
Pg. 340-346
Jan/Feb 2021
Pg. 73-81
Jan/Feb 2019
Pg. 59
Author(s): Allen Loyd V Jr
May/Jun 2017
Pg. 247-250
Jul/Aug 2014
Pg. 287-290
Nov/Dec 2023
Pg. 512-521
Mar/Apr 2022
Pg. 163-174
Jul/Aug 2021
Pg. 304-309
Author(s): Allen Loyd V Jr
May/Jun 2019
Pg. 258-263
Nov/Dec 2017
Pg. 468
Author(s): Blankenship Cynthia
Jan/Feb 2026
Pg. 78-87
Nov/Dec 2025
Pg. 505-519
Mar/Apr 2025
Pg. 150-162
Nov/Dec 2012
Pg. 471-474
Author(s): Osteen Richard
Jul/Aug 2016
Pg. 298-305
Author(s): Allen Loyd V Jr